Agoracom Blog Home

Archive for the ‘All Recent Posts’ Category

Victory Square $VST.ca $VSQTF Technologies Signs Binding Letter of Intent to Acquire IV Hydreight, An On-Demand & On-Site Mobile #Health, #Pharmaceutical & #Wellness Service Provider Across the United States $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 9:19 AM on Tuesday, January 19th, 2021
Victory Square Technologies | LinkedIn
  • Hydreight provides a completely compliant turnkey business model for health professionals to offer fully licensed medical, health & wellness services through an on-demand and on-site platform.

  • In addition to providing telehealth services, Hydreight also provides a diverse suite of health & wellness protocols that include IV drip, Botox, COVID-19 testing, and other medical and medispa treatments.

  • Hydreight is a USA certified e-script and telemedicine provider, allowing Hydreight to offer a wide array of health and medical services in all 50 states.

  • Hydreight provides full pharmaceutical offerings across the United States (Hydreight has full 503B Pharmaceutical supply capabilities ).
  • Hydreight has established key relationships and supply network chains with major vendors including: Medline, Mckesson, Allergan (Botox), Galderma and numerous pharmacies.

VANCOUVER, British Columbia, Jan. 19, 2021 — Victory Square Technologies Inc. (” Victory Square ” or the “ Company ”) (CSE:VST) (OTC:VSQTF) (FWB:6F6), a company that provides investors access to a diverse portfolio of companies in key sectors including: digital health, gaming, blockchain, AR/VR, cybersecurity, and cloud computing, is pleased to announce that it has signed a binding letter of intent (the “ LOI ”) dated January 13, 2021 in respect of the acquisition (the “ Acquisition ”) of all of the shares of IV Hydreight Inc. (“ Hydreight ”), a mobile health and wellness service provider operating in the United States.

Founded in 2018, Hydreight provides a unique, custom built, proprietary telemedicine service that allows users to book confidential health & wellness and/or medical services at their home, hotel, office or wherever they may need discreet assistance. The business model of Hydreight leverages decentralized healthcare to bring quality telehealth, medical, health and wellness services to the masses in an efficient, scalable and cost effective way.

Read More: https://agoracom.com/ir/VictorySquareTechnologies/forums/discussion/topics/753355-victory-square-technologies-signs-binding-letter-of-intent-to-acquire-iv-hydreight-an-on-demand-on-site-mobile-health-pharmaceutical-wellness/messages/2298763#message

FansUnite $FANS.ca $FUNFF Enters into Partnership with OneComply to Assist with U.S. Licensing Strategy $SCR.ca $BRAG.ca $TNA.ca $FDM.ca $JJ.ca

Posted by AGORACOM-JC at 7:56 AM on Tuesday, January 19th, 2021
  • FansUnite Entertainment Inc. and Vancouver-based OneComply Inc. have entered into a partnership. OneComply, a compliance and licensing solution, will assist FansUnite as they enter additional North American legalized gaming jurisdictions by advising on protocol and strategy.
  • This move follows the June 2020 announcement by FansUnite of the amalgamation with Vancouver-based Askott Entertainment Inc. to create one of Canada’s leading online gaming companies, focused on sports betting, esports wagering, and casino games.

Vancouver, British Columbia–(January 19, 2021) –  FansUnite Entertainment Inc. (CSE: FANS) (OTCQB: FUNFF) (“FansUnite” or the “Company”) and Vancouver-based OneComply Inc. (“OneComply”) have entered into a partnership. OneComply, a compliance and licensing solution, will assist FansUnite as they enter additional North American legalized gaming jurisdictions by advising on protocol and strategy.

This move follows the June 2020 announcement by FansUnite of the amalgamation with Vancouver-based Askott Entertainment Inc. to create one of Canada’s leading online gaming companies, focused on sports betting, esports wagering, and casino games.

“We are pleased to be partnering with OneComply as we look to tackle the North American gaming market,” said Scott Burton, CEO of FansUnite. “As a licensed betting and iGaming company, we understand how difficult and nuanced the licensing process can be. With the help of OneComply, we will be able to streamline the process to enter new North American markets and showcase our suite of gaming solutions to a broader audience.”

The repeal of PASPA, being the Professional and Amateur Sports Protection Act, has created a wave of newly regulated States across the United States’ gaming market. Companies seeking to gain market entry into these States face massive regulatory processes to obtain operational licenses. The United States legalized gaming industry is State-regulated, meaning companies need to file for each jurisdiction independently. These individual disclosure filings can be thousands of pages in size resulting in substantial internal and external expenses.

“The amount of opportunity in North America for new-to-market companies can be overwhelming given the various licensing processes and jurisdictional requirements, with companies no longer trying to enter one jurisdiction, but multiple jurisdictions simultaneously. This creates a tremendous amount of lag in productivity even with the most seasoned of compliance and legal teams,” said Cameron Conn, CEO of OneComply Inc. “We understand the importance FansUnite places on regulation, and we look forward to supporting them scale in the North American market.”

Read More: https://agoracom.com/ir/FansUniteEntertainment/forums/discussion/topics/753353-fansunite-enters-into-partnership-with-onecomply-to-assist-with-u-s-licensing-strategy/messages/2298761#message

Candente Gold Changes Name to Xali Gold Corp. $XGC.ca $FMG.ca $MEX.ca $AGI.ca $DSV.ca

Posted by AGORACOM at 6:16 PM on Monday, January 18th, 2021

Candente Gold Corp. (TSXV:CDG) (“Candente Gold” and/or the “Company”) is pleased to announce that the Company will change its name to Xali Gold Corp. on Tuesday January 19th, 2021. The new trading symbol will be XGC, CUSIP number will be 98387F103 and ISIN will be CA98387F1036. The website will also be changed to www.xaligold.com.

About Xali Gold
Xali Gold has launched a comprehensive growth strategy to build a cash flowing business platform and gain access to properties with near surface exploration potential while maintaining El Oro as its flagship asset and an integral part of the overall growth strategy. The acquisition of the SDA Plant, the El Dorado historic mines and the Cocula Project signify important initial steps.

The financial benefits from Western Mexico operations and the addition of specialized personnel will translate across platforms to strengthen the Company’s efforts to explore and potentially mine areas demonstrated to contain mineralization of value. The Company is currently evaluating other properties that are complementary to the SDA plant, El Dorado and the Cocula Project.

Read More: https://agoracom.com/ir/XaliGold/forums/discussion/topics/753330-candente-gold-changes-name-to-xali-gold-corp/messages/2298688#message

‘Ensure that your diet is 90% to 100% plant-based’: 9 food rules from the world’s longest-living people SPONSOR: PlantX Life $VEGA.ca $PLTXF $BYND $TSN $CAG $FMCI $VERY $MEAT

Posted by AGORACOM-JC at 1:39 PM on Monday, January 18th, 2021

SPONSOR: PlantX Life (VEGA:CSE) (PLTXF:OTCQB)

The paradigm shifting, parabolic growth of plant based foods and a plant based life is unstoppable, with the plant-based food market alone expected to reach $74.2 billion by 2027.

PlantX Life (VEGA:CSE) (PLTXF:OTCQB) Is The One Stop Shop For Everything Plant Based + The  Digital Face of The Plant -Based Community with the following:

  • Plant Based Meal Delivery (20 meals)
  • Plant Based Snack Products
  • Plant Based Pet foods
  • Plant Based Restaurant Locator
  • Plant Based Recipes
  • Plant Based Essentials …. Like Chocolate (Essential?  You Bet)
  • And …… Plant Based …. PLANTS (It’s A BIG Business!)

More than just talk, VEGA is already in full swing and growing FAST

  • Already Operating In Canada
  • US Online Operations Kick Off With $USD 25M MIN of PlantX products YEAR 1
    • 6% Royalty Fee to PlantX on gross USA revenues
  • £8 million Acquisition of Bloombox In The UK, generating millions in revenue
  • Closed $11.5M Non-Brokered Private Placement
  • Monthly gross revenue of over $1M for December 2020
  • · ….. and just announced its Application To List On NASDAQ

Hub On AGORACOM / Corporate Profile

‘Ensure that your diet is 90% to 100% plant-based’: 9 food rules from the world’s longest-living people

By: Dan Buettner, Contributor

More than 15 years ago, I set out to reverse-engineer a formula for longevity. Working with renowned doctors and nutritionists, I identified several Blue Zones: Places around the world where people live the longest.

Along the way, I met experts who helped me understand why the foods people ate led to longer lives. We also distilled 150 dietary surveys of centenarians, or those who live to 100 or longer, to reveal the secrets of a strong longevity regimen.

These nine simple guidelines reflect what foods (and how of much of it) Blue Zone residents eat to stay healthy:

1. Ensure that your diet is 90% to 100% plant-based.

Centenarians eat an impressive variety of garden vegetables and leafy greens (especially spinach, kale, beet and turnip tops, chard and collards) when they are in season.

During the off-season, they pickle or dry the surplus. Beans, greens, sweet potatoes, whole grains, fruits, nuts and seeds dominate Blue Zone meals all year long.

Olive oil is also a staple. Evidence shows that olive oil consumption increases good cholesterol and lowers bad cholesterol. In the Greek island Ikaria, for example, we found that for middle-aged people, about six tablespoons of olive oil daily seemed to cut the risk of premature mortality by 50%.

2. Retreat from meat.

On average, Blue Zone residents eat about two ounces or less of meat about five times per month (usually as a celebratory food, a small side, or as a way to flavor dishes).

One 12-year study, which followed a community of 96,000 Americans in Loma Linda — a Blue Zone region in California — determined that people who lived the longest were vegans or pesco-vegetarians who ate a small amount of fish.

Vegetarians in Loma Linda, according to the researchers, were more likely to outlive their meat-eating counterparts by as many as eight years.

Okinawans in Japan probably offer the best meat substitute: Extra-firm tofu, which is high in protein and cancer-fighting phytoestrogens.

3. Go easy on fish.

In most Blue Zones, people ate small amounts of fish, fewer than three ounces up to three times weekly.

Usually, the fish being eaten are small, relatively inexpensive varieties like sardines, anchovies and cod —species in the middle of the food chain that are not exposed to the high levels of mercury or other chemicals that pollute our gourmet fish supply today.

Again, fish is not a necessary part of a longevity diet, but if you must eat it, elect varieties that are common and not threatened by overfishing.

4. Eat a daily dose of beans.

Beans reign supreme in Blue Zones and are the cornerstone of every longevity diet in the world: Black beans in Nicoya; lentils, garbanzo and white beans in the Mediterranean; and soybeans in Okinawa.

Most centenarians eat at least four times as many beans as Americans do on average — at least a half cup per day. And so should you. Why? Beans are packed with more nutrients per gram than any other food on Earth.

On average, they are made up of 21% protein, 77% complex carbohydrates, and only a few percent fat. Because they are fiber-rich and satisfying, they’ll likely help to push less healthy foods out of your diet.

5. Slash sugar.

Blue Zone communities eat sugar intentionally, not by habit or accident.

They consume about the same amount of naturally occurring sugars as North Americans do, but only about a fifth as much added sugar — no more than seven teaspoons a day.

Between 1970 and 2000, the amount of added sugar in the American food supply rose by 25% (about 22 teaspoons of added sugar per day) — generally, the result of the insidious, hidden sugars mixed into soda, yogurt and sauces.

If you must eat sweets, save cookies, candy and bakery items for special occasions (ideally as part of a meal). Limit sugar added to coffee, tea or other foods to no more than four teaspoons per day.

Skip any product that lists sugar among its first five ingredients.

6. Snack on nuts.

Eat two handfuls of nuts per day.

A handful weighs about two ounces, the average amount that Blue Zone centenarians consume: Almonds in Ikaria and Sardinia, pistachios in Nicoya, and all varieties of nuts with the Adventists in Loma Linda.

A study on food and longevity found that nut eaters outlive non-nut eaters by an average of two to three years. So try to snack on a couple handfuls of almonds, Brazil nuts, cashews, walnuts, or peanuts every day.

7. Sour on bread.

If you can, strive to eat only sourdough or 100% whole wheat bread.

Most commercially available breads start with bleached white flour, which metabolizes quickly into sugar and spikes insulin levels.

But bread in Blue Zones is either whole grain or sourdough. In Ikaria and Sardinia, breads are made from a variety of whole grains such as wheat, rye or barley, each of which offers a wide spectrum of nutrients.

Whole grains have higher levels of fiber than most commonly used bleached flours. Some traditional Blue Zone breads are made with naturally occurring bacteria called lactobacilli, which “digest” the starches and glutens while making the bread rise.

The process also creates an acid — the “sour” in sourdough. The result is bread with less gluten than breads labeled “gluten-free,” with a longer shelf life and a pleasantly sour taste that most people like.

8. Drink mostly water.

If possible, strive to avoid soft drinks, including diet soda. With very few exceptions, people in Blue Zones drink only coffee, tea, water and wine.

(Soft drinks, which account for about half of Americans’ sugar intake, were unknown to most Blue Zone centenarians until recently.)

Here’s why:

  • Water: Adventists recommend seven glasses of water daily. They point to studies showing that being hydrated facilitates blood flow and lessens the chance of a blood clot.
  • Coffee: Sardinians, Ikarians, and Nicoyans all drink coffee. Research associates coffee with lower rates of dementia and Parkinson’s disease.
  • Tea: Okinawans prefer green varieties, which have been shown to lower the risk of heart disease and several cancers. Ikarians drink brews of rosemary, wild sage and dandelion — all herbs known to have anti-inflammatory properties.
  • Red Wine: People who drink — in moderation — tend to outlive those who don’t. (This doesn’t mean you should start drinking if you don’t drink now.) People in most Blue Zones drink one to three small glasses of red wine per day, often with a meal and with friends.

9. Go whole.

We found that most centenarians traditionally eat whole foods.

These are foods made from single ingredient — raw, cooked, ground or fermented — and are not highly processed. They eat raw fruits and vegetables; they grind whole grains themselves and then cook them slowly.

They also use fermentation — an ancient way to make nutrients bioavailable — in the tofu, sourdough bread, wine and pickled vegetables they eat.

And they rarely ingest artificial preservatives. Blue zones dishes typically contain a half dozen or so ingredients, simply blended together.

Dan Buettner is a longevity researcher, National Geographic Fellow and award-winning journalist. He is the author of “The Blue Zones Solution” His latest bestseller, “The Blue Zones Kitchen,” fuses scientific reporting, National Geographic photography and recipes that may help you live to 100. Follow him on Instagram @DanBuettner.

Source: https://www.cnbc.com/2020/12/10/90-to-100-plant-based-diet-food-longevity-secrets-from-people-who-live-to-100-or-longer.html

Tartisan Nickel $TN.ca: Poised For A Breakout Year! Resource Expansion & Exploration Ramp Up IS Coming IN 2021 $RNX.ca $TSLA $NOB.ca $SHL.ca $CNC.ca $FPC.ca $NICO.ca

Posted by AGORACOM at 10:33 AM on Monday, January 18th, 2021
Tc logo in black

Morgan Stanley on Nickel Forecast:

  • 6.4% demand growth in 2021
    • outpacing supply as Indo NPI growth offset by China’s decline
  • Market moving from 85kt surplus in 2020 to -18kt in ’21
    • Supporting average price of $7.29/lb, with risk skewed to bull case $8.75/lb

Tartisan Investment Highlights:

  • Kenbridge Nickel Deposit is a Class 1 Nickel project which can safely be put into production quickly at low capital cost
  • Updated Mineral Resource Estimate: 7.47 Ktonnes 0.6% Ni, 0.32% Cu open pit and underground
  • Measured and Indicated resources 985 Ktonnes Inferred at 1% Ni, 0.62% or 117 million pounds of Nickel and 66 million pounds of Copper
  • Potential to double the underground resource at Kenbridge through anticipated drill program
  • Kenbridge North – Untested Potential to Discover additional Class 1 Deposits

Tartisan Strategic Investment Holdings $9+ Million

  • Eloro Resources,  Class One Nickel and Technologies , Peruvian Metals Corp. provide Tartisan shareholders an opportunity to participate in other high-quality projects

Kenbridge Ni Project (Kenora, Ontario)

  • Property is accessible via gravel roads from paved Highway 71
  • Underground development of the deposit extends from surface to a depth of 623 metres in a 3 compartment shaft, with 244 metres of drifts and 168 metres of crosscuts at the 110 and 150 metre levels
  • The minimum drill spacing is at 15.2metres on all levels.
  • The deepest hole extends to 838.4 metre depth and intersected mineralization grading 4.25% nickel and 1.38% copper over 10.7 metres, indicating that the deposit remains open at depth.
  • Historical surface drilling was completed at 30.5metre spacing
  • Preliminary  Economic Assessment completed and updated returned robust project economics and operating costs including a NPV of C$253M and cash costs of US$3.47/lb of nickel net of copper credits

Look for Tartisan Corporate updates in 2021 at Tartisan.com

XPhyto $XPHY.ca Announces Business Strategy and Milestones For 2021 Innovation to Impact $NGM.ca $SONA.ca $HBP.ca $MIR.ca $IPA.ca

Posted by AGORACOM at 7:41 AM on Monday, January 18th, 2021
  • Commercialization of rapid COVID-19 PCR test
  • Clinical validation of transdermal and sublingual drug formulations
  • Psychedelic API production, drug formulation and clinical integration

XPhyto Therapeutics Corp. (CSE:XPHY / OTCQB:XPHYF / FSE:4XT) (“XPhyto” or the “Company“) is pleased to announce its business strategy and milestones for 2021. The Company is on the cusp of transformational change as product development programs advance from the laboratory to the clinic. As a bioscience accelerator at the leading-edge of the life science industry, XPhyto will target growth through commercialization of existing products and focused investment in impact driven innovation with the potential for extreme value creation.

The Company will continue to leverage its scientific expertise and operations in Europe and North America for product development and optimization while it plans to add significant commercial experience in the fields of manufacturing, distribution, marketing and sales. Following a successful business year 2020, XPhyto is well positioned to execute on important core milestones in all business divisions, which include the commercialization of infectious disease diagnostics, the clinical validation of transdermal and sublingual drug formulations and continued investment and development in psychedelic medicine.

Diagnostics

XPhyto’s lead diagnostic product is an accurate, rapid and highly portable PCR diagnostic test system which is secured under an exclusive global commercialization agreement from its German development partner, 3a-diagnostics GmbH (“3a”). PCR testing has emerged as the only internationally recognized standard for COVID-19 testing, which is expected to play a critical role in expediting the revitalization of many industries, particularly domestic and international travel. Successful validation of the PCR system was achieved in Q4 2020 and the Company is confident that European commercial (CE-IVD) approval will be achieved in Q1 2021. XPhyto is in discussions to secure manufacturing and distribution partners in Europe and the Middle East in anticipation of pending commercial approval and product launch in Q1 2021.

In addition to COVID-19 products, XPhyto and its partner 3a, are developing and commercializing a portfolio of low-cost oral biosensors. The Company’s lead biosensor product is an oral health screening test for the detection of peri-implantitis. There is a significant clinical need for the early detection of infection associated with dental implants prior to the onset of irreversible tissue and bone damage. The company is targeting late 2021 for European commercial approval and product launch for several biosensor screening tests.

Drug Formulations and Delivery

XPhyto’s drug formulation business is focused on neurological indications with significant market demand and the potential for meaningful patient impact. In 2020, XPhyto’s German subsidiary, Vektor Pharma TF GmbH (“Vektor”), a leader in the development of transdermal and sublingual drug formulations reported significant advancements in four therapeutic development programs. Vektor also successfully developed a sublingual drug formulation on contract for a major generic drug manufacturer and distributor.

In 2021, the Company plans to complete human pilot studies on its four lead therapeutic products: 1) Rotigotine transdermal patch for Parkinson’s disease; 2) CBD oral/sublingual strip for treatment resistant Epilepsy; 3) THC oral/sublingual strip for anorexia/nausea; and 4) CBD:THC (1:1) oral/sublingual strip for Multiple Sclerosis associated spasticity. The Company is currently in ongoing discussions with multiple potential commercial partners, licensors and distributors and will be reviewing monetization opportunities on a continued basis.

Psychedelics

Psychedelic compounds are a highly promising new class of active pharmaceutical ingredient (“API”) with strong potential for the treatment of mental health related medical conditions such as depression, anxiety, addiction, and trauma-related stress disorder. Psychedelics could provide a major improvement over currently available therapeutics for a global market with unmet medical need.

XPhyto has entered into two psychedelic agreements: first, for the development of industrial scale biotechnology processes for the production of psilocybin, and second, for research and development related to multiple psychedelic compounds, including psilocybin, mescaline, LSD, MDMA, DMT, among others.

Read More: https://agoracom.com/ir/XphytoTherapeutics/forums/discussion/topics/753246-xphyto-announces-business-strategy-and-milestones-for-2021-innovation-to-impact/messages/2298545#message

The COVID-19 Treatment Guidelines Panel’s Statement on the Use of Ivermectin for the Treatment of COVID-19 SPONSOR: Mountain Valley MD $MVMD.ca $CTLT $MRNA $NVAX

Posted by AGORACOM at 12:53 PM on Friday, January 15th, 2021

SPONSOR: Mountain Valley MD has confirmed the ability to make the drug ivermectin water-soluble without the use of organic solvents, greatly increasing the potential applications for treatment. MVMD has Improved ivermectin’s water solubility by nearly 5000 times more than current solubility  Click Here for More Info

  • The NIH has upgraded their recommendation and now consider IVERMECTIN an option for use! The national Institute of Health

Recommendation

  • The COVID-19 Treatment Guidelines Panel (the Panel) has determined that currently there are insufficient data to recommend either for or against the use of ivermectin for the treatment of COVID-19. Results from adequately powered, well-designed, and well-conducted clinical trials are needed to provide more specific, evidence-based guidance on the role of ivermectin for the treatment of COVID-19.

Rationale

Ivermectin is an antiparasitic drug that is approved by the Food and Drug Administration (FDA) for the treatment of onchocerciasis and strongyloidiasis. Ivermectin is not FDA-approved for the treatment of any viral infection. In general, the drug is well tolerated. It is currently being evaluated as a potential treatment for COVID-19.

Antiviral and Anti-Inflammatory Effects of Ivermectin

Reports from in vitro studies suggest that ivermectin acts by inhibiting the host importin alfa/beta-1 nuclear transport proteins, which are part of a key intracellular transport process that viruses hijack to enhance infection by suppressing the host antiviral response.1,2 In addition, ivermectin docking in vitro may interfere with the attachment of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein to the human cell membrane.3

Ivermectin has been shown to inhibit the replication of SARS-CoV-2 in cell culture. However, pharmacokinetic and pharmacodynamic studies suggest that ivermectin doses up to 100-fold higher than those approved for use in humans would be required to achieve the plasma concentrations necessary to duplicate the drug’s antiviral efficacy in vitro.4,5 Even though ivermectin appears to accumulate in lung tissue, with the doses used in most clinical trials, predicted systemic plasma and lung tissue concentrations are much lower than 2 µM, the half-maximal inhibitory concentration (IC50) against SARS-CoV-2 in vitro.6,7

Ivermectin demonstrates potential anti-inflammatory properties in some in vitro studies,8,9 properties which have been postulated to be beneficial in the treatment of COVID-19.10

Clinical Data

Since the last revision of the Ivermectin section of the Guidelines, the results of several randomized trials and retrospective cohort studies of ivermectin use in patients with COVID-19 have been published in peer-reviewed journals or made available as preliminary, non-peer-reviewed reports. Some clinical studies showed no benefits or worsening of disease after ivermectin use,11-14 whereas others reported shorter time to resolution of disease manifestations attributed to COVID-19,15-18 greater reduction in inflammatory markers,16,17 shorter time to viral clearance,11,16 or lower mortality rates in patients who received ivermectin than in patients who received comparator drugs or placebo.11,16,18

However, most of the studies reported to date had incomplete information and significant methodological limitations, which make it difficult to exclude common causes of bias. The missing information and limitations include the following:

  • The sample size of most of the trials was small.
  • Various doses and schedules of ivermectin were used.
  • Some of the randomized controlled trials were open-label studies in which neither the participants nor the investigators were blinded to the treatment arms.
  • In addition to ivermectin or the comparator drug, patients also received various concomitant medications (e.g., doxycycline, hydroxychloroquine, azithromycin, zinc, corticosteroids), confounding assessment of the true efficacy or safety of ivermectin.
  • The severity of COVID-19 in the study participants was not always well described.
  • The study outcome measures were not always clearly defined.

Because of these limitations, the Panel cannot draw definitive conclusions about the clinical efficacy or safety of ivermectin for the treatment of COVID-19. Results from adequately powered, well-designed, and well-conducted clinical trials are needed to provide more specific, evidence-based guidance on the role of ivermectin for the treatment of COVID-19.

SOURCE: https://www.covid19treatmentguidelines.nih.gov/statement-on-ivermectin/

Gratomic $GRAT.ca $CBULF Defines Product Marketing Strategy as Construction Advances at Aukam Graphite Mine $NGC.ca $LLG.ca $GPH.ca $NOU.ca $NMI.ca #TODAQ

Posted by AGORACOM at 8:15 AM on Friday, January 15th, 2021
  • Foundations of its product marketing and sales strategy have been officially defined

Gratomic Inc. (TSXV:GRAT)(FSE:CB82)(WKN:A143MR)(OTCQB:CBULF) is pleased to announce that the foundations of its product marketing and sales strategy have been officially defined.

During the commissioning phase, due to begin in March 2021, the company will be testing production quality and quantity. In order to support this development, Gratomic has plans in place to upgrade its laboratory facilities at Aukam. This will enable us to properly characterize the initial production batches generated during the commissioning process, and feedback the information to our Process Control, in order to define parameters required to ensure repeatability and efficiency of the production.

As a supplement to our main strategic focus on the battery industry and graphene applications (see press release from Dec 30th, 2020), Gratomic will pursue the development of graphite grades commonly used in applications such as graphitic foil, lubricants, crucibles, refractories, friction materials and ceramics, among others.

This will allow the Company to diversify our portfolio and optimize the output of the processing plant. Filling the remainder of the Aukam Book in terms of offtake and purchase schedules. In the coming weeks, Gratomic will pursue the preparation of samples for 53 graphite end users around the world, in order to begin the testing and homologation procedures that precede the use of our product into the most technical applications.

Gratomic’s Product Marketing team has requested an additional 550 kg of graphite samples be shipped to Toronto for conversion to SG16 Battery Grade product specifications in addition to the initial shipment of 243Kg of graphite, which was previously dispatched (see press release from Oct 28,2020). Both samples are destined for distribution to Battery OEM Manufacturers.

Read More: https://agoracom.com/ir/Gratomic/forums/discussion/topics/753096-gratomic-defines-product-marketing-strategy-as-construction-advances-at-aukam-graphite-mine/messages/2298104#message

VIDEO – After Record Q3 and YTD Results, Datametrex $DM.ca $DTMXF Starts 2021 With 23,000 #COVID Test Sales To Film Industry For ~ $4M $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM-JC at 8:34 PM on Thursday, January 14th, 2021

Datamerex (DM:TSXV) has the rare benefit that most small cap companies would only dream of …. 2 successful independent divisions that are each capable of being a company maker. 

The first division is their Artificial Intelligence driven social media monitoring and discovery product … and this isn’t some basic social media monitoring tool for keywords. Clients include Canadian Federal Government, DRDC, Health Canada, United States Air Force and LOTTE (a $2.6B South Korean multinational conglomerate.

As a result of the highest level security clearances required to do this level of work, Datametrex was well positioned with deep roots in South Korea to add their second, though unintended division of COVID-19 test kit distribution.  Again, this isn’t some small cap stretch trying to capitalize on a trend for the sake of stock promotion. Rather, when the Canadian Government came calling for assistance in importing and distributing COVID-19 test kits, Datametrex stepped up to the task thanks to its security clearances already in place in both countries.

Since then, the company has signed multiple multi-million dollar COVID-19 test kit supply agreements with mining companies, a $20M CAD agreement with the television and film industry and various educational institutions.  

As a result, Datametrex has had its’ best year ever in the first 3 quarters of 2020 as follows:

  • Record revenue of $7.6 million for the nine-month 2020 period compared to $2.6 in 2019
  • Record revenue of $4.9 million was generated in Q3
  • First ever positive EBIDTA quarter

If that wasn’t enough, they started off 2021 by announcing the following:

  • Sold over 23,000 onsite tests for the film industry at locations in Montreal, Toronto and Vancouver for the months of October through December 2020. This represents approximately $4,000,000 CAD in top-line revenue for Q4
  • Datametrex Providing COVID-19 Testing for Air Canada Front-Line and Inflight Employees
  • Binding LOI to acquire 100% of Concierge Medical Consultant Inc. a private telehealth and medical concierge services company currently generating revenue through a direct-to-consumer subscription model

Watch this powerful interview with CEO Marshall Gunter to discuss the year that was … and why he’s so optimistic about 2021.

Innocan Pharma $INNO.ca Successfully Completes Large Scale Production of Exosomes $IN.ca $AXIM $LABS $CRDL.ca $TBP.ca

Posted by AGORACOM-JC at 4:15 PM on Thursday, January 14th, 2021
Innocan-Blog
  • Announced the successful completion of a large-scale production of exosomes
  • Innocan’s CBD Loaded Exosome (CLX) Therapy project led by Prof. Offen demonstrates the capability of having reliable large-scale production of exosomes and is an important milestone in the CLX Therapy development process.
  • Innocan managed to perform the production of trillions of exosomes in a short period of time in a 3-dimensional bioreactor, and that may lead to economic large scale exosome production for the CLX.
  • This achievement is expected to pave the way for larger tests and studies.

Herzliya, Israel and Calgary, Alberta–(January 14, 2021) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC Pink: INNPF) (the “Company” or “Innocan“), is pleased to announce the successful completion of a large-scale production of exosomes. Innocan’s CBD Loaded Exosome (CLX) Therapy project led by Prof. Offen demonstrates the capability of having reliable large-scale production of exosomes and is an important milestone in the CLX Therapy development process. Innocan managed to perform the production of trillions of exosomes in a short period of time in a 3-dimensional bioreactor, and that may lead to economic large scale exosome production for the CLX. This achievement is expected to pave the way for larger tests and studies.

“Innocan is now one of a few public companies in the exosome’s science field. Although we are still in the development stage of the CLX platform, large scale exosome production capabilities are a significant proof of advantage and capability for Innocan, as part of the path to commercialization,” said Iris Bincovich, founder and CEO of Innocan.

Innocan Pharma together with Tel Aviv University, Prof. Offen and his team, are developing a new revolutionary cell therapy – based technology, loaded with CBD (Cannabidiol), designed to target coronavirus infected lung cells and central nervous system diseases. The CLX Therapy holds the potential to provide a highly synergistic effect of anti-inflammatory properties and help in the recovery of infected lung cells. This product is planned to act as a “guided missile” to the infected lungs, combining the cell healing properties of exosomes and the anti-inflammatory properties of CBD.